Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Paoletti

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Nerve growth factor regulates axial rotation during early stages of chick embryo developmentAnnalisa Manca, Simona Capsoni, Anna Di Luzio, et al.
Plos One|June 6, 2012
Intranasal "painless" human Nerve Growth Factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in App X PS1 miceSimona Capsoni, Sara Marinelli, Marcello Ceci, et al.
Biochemical and Biophysical Research Communications|December 1, 2009
In vitro receptor binding properties of a "painless" NGF mutein, linked to hereditary sensory autonomic neuropathy type VSonia Covaceuszach, Simona Capsoni, Sara Marinelli, et al.
AIDS Research and Human Retroviruses|May 29, 2010
Mutational resistance pattern of HIV type 1 in CD14+ monocytes, CD4+ T cells, and plasma from treated patientsOmbretta Turriziani, Arianna Boni, Francesca Falasca, et al.
Current HIV Research|October 4, 2017
Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population: Results from the Ral-Age StudyPaolo Pavone, Noemi Giustini, Caterina Fimiani, et al.
Structure (London, England : 1993)|November 6, 2018
The Structure of the Pro-domain of Mouse proNGF in Contact with the NGF DomainRobert Yan, Havva Yalinca, Francesca Paoletti, et al.
Scandinavian Journal of Infectious Diseases|October 29, 2013
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)Massimiliano Fabbiani, Annalisa Mondi, Manuela Colafigli, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Nerve growth factor regulates axial rotation during early stages of chick embryo developmentAnnalisa Manca, Simona Capsoni, Anna Di Luzio, et al.
Plos One|June 6, 2012
Intranasal "painless" human Nerve Growth Factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in App X PS1 miceSimona Capsoni, Sara Marinelli, Marcello Ceci, et al.
Biochemical and Biophysical Research Communications|December 1, 2009
In vitro receptor binding properties of a "painless" NGF mutein, linked to hereditary sensory autonomic neuropathy type VSonia Covaceuszach, Simona Capsoni, Sara Marinelli, et al.
AIDS Research and Human Retroviruses|May 29, 2010
Mutational resistance pattern of HIV type 1 in CD14+ monocytes, CD4+ T cells, and plasma from treated patientsOmbretta Turriziani, Arianna Boni, Francesca Falasca, et al.
Current HIV Research|October 4, 2017
Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population: Results from the Ral-Age StudyPaolo Pavone, Noemi Giustini, Caterina Fimiani, et al.
Structure (London, England : 1993)|November 6, 2018
The Structure of the Pro-domain of Mouse proNGF in Contact with the NGF DomainRobert Yan, Havva Yalinca, Francesca Paoletti, et al.
Scandinavian Journal of Infectious Diseases|October 29, 2013
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)Massimiliano Fabbiani, Annalisa Mondi, Manuela Colafigli, et al.
Pageof 3